Table 1.

Echocardiography at week 6 after induction of the aorto-caval fistula and after 2 weeks of treatment with the soluble epoxide hydrolase inhibitor.

	Group
Parameter	FHL	FHL	ACF FHL	ACF FHL	FHH	FHH	ACF FHH	ACF FHH
	+	+	+	+	+	+	+	+
	water	sEHi	water	sEHi	water	sEHi	water	sEHi
Heart weight (mg)/Body weight (g)	2.78 ± 0.09	2.84 ± 0.08	4.99 ± 0.21*	5.12 ± 0.26*	3.21 ± 0.08#	3.22 ± 0.09#	5.34 ± 0.36*	5.30 ± 0.32*
RV diastolic diameter (mm)	3.25 ± 0.24	3.41 ± 0.29	6.19 ± 0.27*	6.24 ± 0.26*	3.31 ± 0.22	3.36 ± 0.27	6.21 ± 0.24*	6.20 ± 0.28*
LV diastolic diameter (mm)	6.19 ± 0.43	6.16 ± 0.47	11.02 ± 0.39*	10.99 ± 0.41*	6.17 ± 0.31	6.22 ± 0.33	10.87 ± 0.39*	11.04 ± 0.48*
LV systolic diameter (mm)	3.14 ± 0.38	3.17 ± 0.34	7.14 ± 0.38*	7.08 ± 0.34*	3.26 ± 0.21	3.27 ± 0.23	7.06 ± 0.24*	7.11 ± 0.27*
LV posterior wall thickness in diastole (mm)	2.36 ± 0.31	2.31 ± 0.29	2.27 ± 0.31	2.26 ± 0.29	2.96 ± 0.11	2.98 ± 0.10	2.28 ± 0.13	2.27 ± 0.13
Interventricular septum thickness (mm)	2.25 ± 0.18	2.23 ± 0.17	2.17 ± 0.17	2.18 ± 0.09	2.61 ± 0.17	2.63 ± 0.18	2.16 ± 0.18	2.17 ± 0.17
LV relative wall thickness (mm)	0.71 ± 0.05	0.69 ± 0.04	0.41 ± 0.03*	0.39 ± 0.04*	0.78 ± 0.04	0.79 ± 0.04	0.40 ± 0.03*	0.39 ± 0.03*
LV fractional shortening (%)	63 ± 3	61 ± 3	47 ± 2*	46 ± 2*	61 ± 3	62 ± 3	48 ± 2*	46 ± 3*
Stroke volume (μl)	206 ± 9	211 ± 8	556 ± 2*	562 ± 31*	209 ± 11	207 ± 9	573 ± 29*	569 ± 28*
Cardiac output (ml.min1)	108 ± 9	111 ± 12	308 ± 14*	318 ± 13*	112 ± 10	111 ± 9	321 ± 18*	322 ± 19*

Values are means ± SEM. RV, right ventricle; LV, left ventricle; FHL, fawn-hooded low-pressure rats; FHH, fawn-hooded hypertensive rats; ACF, aorto-caval fistula; sEHi, soluble epoxide hydrolase inhibitor. ^∗P < 0.05 compared with sham-operated counterparts. ^#P < 0.05 FHH vs. FHL.